Aralast alpha1-proteinase Inhibitor Surveillance Study

Baxalta

Status and phase

Terminated

Phase 4

Conditions

Alpha1-antitrypsin Deficiency

Treatments

Drug: ARALAST Alpha1-Proteinase Inhibitor

Study type

Interventional

Funder types

Industry

Identifiers

NCT00313144

450501

Details and patient eligibility

About

The primary objectives of this Phase 4, open label, prospective U.S. surveillance study are to evaluate the health outcomes of Alpha 1-Antitrypsin (AAT)-deficient subjects who are initiating treatment with ARALAST on patient-related outcomes (PRO), i.e., health-related quality of life (HRQoL), healthcare resource utilization (HCRU), and various laboratory analyses to evaluate the safety of long-term administration of ARALAST.

Up to 120 subjects will be enrolled and assessed for HRQoL and HCRU at baseline and every 6-months thereafter, for 2 years. A subset of subjects will be enrolled into the blood draw portion of the study, which will also include assessments of antibodies to ARALAST, and chemistry panel. Subjects will be treated according to the prescribing (attending) physician's instructions based on the prescribing information given in the ARALAST package insert.

Enrollment

127 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female 18 years of age or older
Diagnosis of AAT deficiency associated emphysema
Active prescription for augmentation therapy with ARALAST
On service with Coram (a speciality pharmacy provider)
Signed and dated informed consent

Exclusion criteria

Clinically significant medical (other than COPD), psychiatric, or cognitive illness that, in the opinion of Coram or the sponsor or the investigator, may compromise subject safety or compliance (such as end stage renal or hepatic or heart disease, or metastatic cancer or any difficulty in communicating over the telephone lines)
Previous treatment with ARALAST (i.e. subjects who had previously received and then discontinued ARALAST augmentation therapy and are now restarting ARALAST will be excluded from the study)